Houlihan Lokey
HLI
125.22
-2.72
-2.13%
Houlihan Lokey
US · HLI
#1588 by market cap
Listed 2015
125.22
-2.72
-2.13%
Live - 5344 symbols - heartbeat 80s ago
· 2026-10-08 08:02
Pre-market
123.56
-1.33%
After-hours
125.22
0.00%
- Market cap
- 8.75B
- P/E (TTM)i
- 21.05
- P/Bi
- 3.88
- EPSi
- 6.22
- Div yieldi
- 2.00%
- 52W posi
- 15%
Reader sentiment
Are you bullish or bearish on HLI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.61, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.55% YoY
Margins
- Gross margin
- 38.50%
- Operating margin
- 23.63%
- Net margin
- 16.26%
Key ratios & quality
- PEG ratioi
- 1.12
- Altman Z-Scorei
- 4.61
PEG uses trailing P/E against the 3-year net income growth rate (18.75%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08B | 1.16B | 1.53B | 2.27B | 1.81B | 1.91B | 2.39B | 2.62B |
| Gross profit | 392.31M | 421.61M | 554.26M | 861.32M | 696.64M | 737.05M | 919.93M | 1.01B |
| Selling & admin expenses | 83.22M | 93.30M | 95.56M | 127.81M | 142.90M | 185.32M | 188.48M | 201.12M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 219.10M | 229.60M | 408.16M | 612.86M | 376.81M | 399.10M | 556.32M | 618.54M |
| Pretax profit | 224.32M | 235.65M | 409.23M | 603.94M | 324.00M | 390.54M | 531.34M | 562.27M |
| Tax | 65.21M | 51.85M | 96.46M | 165.61M | 69.78M | 110.24M | 131.62M | 138.09M |
| Net profit | 159.11M | 183.79M | 312.77M | 438.32M | 254.22M | 280.30M | 399.71M | 424.17M |
| Basic EPS | 3 | 3 | 5 | 7 | 4 | 4 | 6 | 6 |
| Diluted EPS | 2.42 | 2.80 | 4.55 | 6.41 | 3.76 | 4.11 | 5.82 | 6.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 666.42M | 605.00M | 659.45M | 717.07M | 635.64M | 511.00M |
| Gross profit | 256.57M | 233.00M | 253.89M | 276.07M | 244.73M | 197.00M |
| Selling & admin expenses | 50.98M | 48.00M | 44.78M | 51.62M | 57.02M | 57.00M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 159.90M | 129.00M | 168.98M | 178.30M | 143.01M | 92.00M |
| Pretax profit | 150.26M | 98.00M | 160.05M | 169.65M | 134.51M | 86.00M |
| Tax | 28.34M | 0 | 48.27M | 53.10M | 36.20M | 8.00M |
| Net profit | 121.92M | 98.00M | 111.78M | 116.55M | 98.31M | 78.00M |
| Basic EPS | 2 | 1 | 2 | 2 | 2 | 1 |
| Diluted EPS | 1.76 | 1.42 | 1.63 | 1.70 | 1.47 | 1.15 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 437.47M | 611.06M | 1.07B | 1.08B | 1.04B | 1.15B | 1.55B | 1.82B |
| Cash & ST investments | 285.75M | 485.68M | 846.85M | 833.70M | 720.69M | 728.80M | 1.14B | 1.32B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.43B | 1.68B | 2.43B | 2.89B | 2.97B | 3.17B | 3.82B | 4.31B |
| Total current liabilities | 495.34M | 501.04M | 812.07M | 1.17B | 919.99M | 873.34M | 1.07B | 1.21B |
| Short-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | 8.66M | 4.68M | 818.00K | 539.00K | -- | -- | -- | -- |
| Total liabilities | 534,583,000.00 | 692,621,000.00 | 1,042,506,000.00 | 1,443,105,000.00 | 1,355,517,000.00 | 1,334,009,000.00 | 1,644,831,000.00 | 1,856,024,000.00 |
| Total equity | 891.33M | 984.38M | 1.38B | 1.44B | 1.61B | 1.84B | 2.17B | 2.45B |
| Retained earnings | 276.47M | 377.47M | 600.10M | 922.22M | 1.03B | 1.16B | 1.39B | 1.65B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.55B | 1.24B | 1.52B | 1.58B | 1.82B | 1.24B |
| Cash & ST investments | 1.14B | 837.13M | 1.08B | 1.14B | 1.32B | 756.00M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 3.82B | 3.52B | 3.79B | 3.94B | 4.31B | 3.72B |
| Total current liabilities | 1.07B | 797.55M | 931.62M | 988.79M | 1.21B | 711.00M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,644,831,000.00 | 1,339,987,000.00 | 1,546,473,000.00 | 1,642,988,000.00 | 1,856,024,000.00 | 1,352,000,000.00 |
| Total equity | 2.17B | 2.18B | 2.25B | 2.29B | 2.45B | 2.37B |
| Retained earnings | 1.39B | 1.45B | 1.52B | 1.59B | 1.65B | 1.67B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 224.27M | 287.67M | 579.84M | 736.60M | 136.27M | 328.46M | 848.61M | 704.13M |
| Depreciation & amortization | 14.48M | 17.29M | 15.23M | 48.54M | 58.22M | 28.54M | 41.27M | 42.63M |
| Free cash flow | 217.55M | 266.95M | 565.69M | 727.92M | 85.54M | 261.73M | 808.91M | 681.82M |
| Dividends paid | -66.93M | -80.66M | -92.01M | -114.81M | -140.38M | -148.45M | -165.22M | -174.04M |
| Stock buybacks / issuance | -69.56M | -29.64M | 86.84M | -304.79M | -48.66M | -24.95M | -52.51M | -175.43M |
| Ending cash balance | 286.12M | 380.75M | 847.22M | 834.07M | 714.81M | 721.85M | 975.58M | 1.19B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 358.38M | -132.00M | 325.42M | 217.68M | 293.03M | -336.00M |
| Depreciation & amortization | 15.41M | 16.00M | 10.29M | 8.30M | 8.04M | 8.00M |
| Free cash flow | 343.90M | -145.00M | 322.99M | 217.04M | 286.78M | -342.00M |
| Dividends paid | -38.52M | -53.00M | -41.25M | -40.63M | -39.16M | -61.00M |
| Stock buybacks / issuance | -52.19M | -8.00M | -29.53M | -87.90M | -50.00M | -50.00M |
| Ending cash balance | 975.58M | 798.00M | 928.40M | 1.06B | 1.19B | 749.00M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 18.24 | 19.60 | 26.42 | 30.97 | 16.63 | 16.25 | 19.93 | 18.85 |
| ROA %i | 11.20 | 11.86 | 15.25 | 16.48 | 8.68 | 9.13 | 11.44 | 10.47 |
| ROIC %i | 18.04 | 17.99 | 23.15 | 27.36 | 14.01 | 13.22 | 16.43 | 15.63 |
| 5-year avg ROE %i | 15.13 | 16.97 | 20.36 | 23.41 | 22.37 | 21.97 | 22.04 | 20.52 |
| EBIT margin %i | 20.24 | 19.80 | 26.76 | 27.00 | 18.89 | 18.95 | 23.28 | 23.63 |
| FCF / sales %i | 20.06 | 23.03 | 37.08 | 32.07 | 4.73 | 13.67 | 33.85 | 26.05 |
| Current ratioi | 0.88 | 1.22 | 1.32 | 0.93 | 1.13 | 1.32 | 1.45 | 1.50 |
| Quick ratioi | 0.88 | 1.22 | 1.32 | 0.93 | 1.13 | 1.32 | 1.45 | 1.50 |
| Debt / assetsi | 0.61 | 9.47 | 7.23 | 6.85 | 12.63 | 13.10 | 11.47 | 11.42 |
| LT debt / equityi | 0.97 | 16.14 | 12.67 | 13.69 | 23.24 | 22.62 | 20.15 | 21.01 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 16.05 | 9.96 | 16.56 | 27.92 | 16.00 | 7.86 | 1.72 | 13.10 |
| Net income CAGR (3Y) %i | 31.64 | 19.26 | 21.99 | 40.12 | 11.42 | -3.59 | -2.98 | 18.75 |
| FCF CAGR (3Y) %i | 353.27 | 3.96 | 32.55 | 49.57 | -31.57 | -22.66 | 3.58 | 99.75 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 19.93 | 20.38 | 20.29 | 20.47 | 18.85 | 18.30 |
| ROA %i | 11.44 | 12.64 | 12.18 | 12.08 | 10.47 | 11.22 |
| ROIC %i | 16.43 | 16.72 | 16.83 | 16.88 | 15.63 | 15.12 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 23.28 | 23.16 | 23.62 | 23.99 | 23.63 | 23.04 |
| FCF / sales %i | 33.85 | 29.80 | 30.54 | 27.90 | 26.05 | 19.21 |
| Current ratioi | 1.45 | 1.56 | 1.63 | 1.60 | 1.50 | 1.74 |
| Quick ratioi | 1.45 | 1.55 | 1.63 | 1.60 | 1.50 | 1.74 |
| Debt / assetsi | 11.47 | 12.52 | 11.41 | 12.63 | 11.42 | 13.26 |
| LT debt / equityi | 20.15 | 20.22 | 19.27 | 21.67 | 21.01 | 21.86 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Corporate Finance is the largest reported line at 59.30% of revenue, across 3 reported segments.
- Financial Restructuring follows at 23.29%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Corporate Finance59.30%
Financial Restructuring23.29%
Financial and Valuation Advisory17.42%
Quote time 2026-10-08 08:02:32 · For reference only, not investment advice and not tailored to your situation.